Cellanome

Cellanome develops a multimodal cellular analysis platform that enables researchers to observe, perturb, and understand the dynamics of cells, cell states, and cellular interactions at scale across any cell type. The company's R3200 Platform is a fully integrated system combining instrumentation, consumables, and software, built around proprietary CellCage technology—biocompatible, tunable micro-environments that preserve native cell morphology and support culturing, time-lapse imaging, perturbation, and sequencing within a unified workflow. By combining fluorescent live-cell imaging with single-cell transcriptomics, Cellanome captures structured, multimodal data with dynamic context, enabling researchers to track how individual cells or functional ensembles shift, interact, and respond over time. The platform serves application areas including neurobiology (uncovering neural states and networks), immunology (revealing how interactions shape immune responses), aging and metabolic disease (decoding cellular senescence at single-cell resolution), and cancer research (linking tumor-immune interactions to RNA programs). The resulting data accelerates therapeutic development and supports AI-ready computational models of biology. Founded in 2020 and headquartered in Palo Alto, California, Cellanome has raised approximately $118.6 million in a Series B round backed by Synetro Group, 8VC, RONA Holdings, General Catalyst, DFJ Growth, and Premji Invest.